New antibody aims to ease stiffness and pain in ankylosing spondylitis
NCT ID NCT05212051
First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time
Summary
This phase 2 trial tests an experimental drug called JS005 in adults with active ankylosing spondylitis, a type of arthritis that mainly affects the spine. Participants receive different doses of JS005 or a placebo as a shot under the skin. The study measures whether JS005 improves symptoms like pain and stiffness after 16 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- an experimental anti-IL-17A antibody called JS005
- What this could lead to
- If successful, JS005 could offer a new treatment option for people with ankylosing spondylitis, helping reduce pain and stiffness.
- What could go wrong
- This is an early-phase trial with a small number of participants, so results may not confirm effectiveness or safety in larger groups.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACTIVE ANKYLOSING SPONDYLITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Anhui Provincial Hospital
Hefei, Anhui, 230001, China
-
Beijing University
Beijing, Beijing Municipality, 100005, China
-
Chuanbei Meidical College Affiliated Hospital
Nanchong, Sichuan, 637000, China
-
Nanfang Hospital of Nandang Medical University
Guangzhou, Guangdong, 510515, China
-
People's Hospital of Xinjiang Uygur Autonomous Region
Ürümqi, Xinjiang, 830001, China
-
Pking University Shenzhen Hospital
Shenzhen, Guangdong, 518036, China
-
Shanghai Changzheng Hospital
Shanghai, Shanghai Municipality, 200003, China
-
Shantou University Medical Collge No.1 Affiliated Hospital
Shantou, Guangdong, 515041, China
-
Shengjing Hospital of China medical University
Shengyang, Liaoning, 110004, China
-
Shenzhen People's Hospital
Shenzhen, Gudong, 518001, China
-
Sun Yat-sen Memorial Sun Yat-sen University City: Guangzhou
Guangzhou, Guangdong, 510120, China
-
The Affilated Hospital of Inner Mongolia Medical University
Hohhot, Inner Mongolia, 100000, China
-
The First Affiliated Hospital of China Medical University
Shenyang, Liaoning, 110001, China
-
The First Affiliated Hospital of Shanxi Medical University
Taiyuan, Shanxi, 650032, China
-
The First Affiliated Hospital of Xiamen University
Shamen, Fujian, 410011, China
-
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, 361001, China
-
The First Hospital of Jilin University
Changchun, Jilin, 130021, China
-
The Second Affiliated Hospital of Dalian Medical University
Dalian, Liaoning, 116023, China
-
The Second Xiangya Hospital of Central South University
Changsha, Hunan, 410013, China
-
The Third Xiangya Hospital of Central South University
Changsha, Hunan, 361001, China
-
Tianjin Medical University General Hospital
Tianjin, Hebei, 300041, China
-
Tongji Hospital Tongji Medical college of HUST
Wuhan, Hubei, 430030, China
-
West China Hospital, Sichuan University
Chengdu, Sichuan, 600041, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.